Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Blood(2020)10.1182/blood.2020008248Source: DataRank Database

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition is a research paper published in Blood (2020). On theSindex it has a DataRank of 0. It has been cited 389 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access389 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 22.20)OA: bronzeTopics (44)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Xuan Yuan ORCID,Hang Chen ORCID,Shruti Chaturvedi ORCID,Evan M. Braunstein ORCID,Robert A. Brodsky ORCID

Live enrichment

PubMed:32877502 PMC:PMC7596849 OpenAlex:https://openalex.org/W3082365904

NHLBI NIH HHS

Grant: R01 HL133113

NHLBI NIH HHS

Grant: K08 HL138142

FWCI

22.20

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronze

journalhttps://ashpublications.org/blood/article-pdf/136/18/2080/1779273/bloodbld2020008248.pdf

publisherhttps://ashpublications.org/blood/article-pdf/136/18/2080/1779273/bloodbld2020008248.pdf

publisherhttp://ashpublications.org/blood/article-pdf/136/18/2080/1779273/bloodbld2020008248.pdf

journalhttps://doi.org/10.1182/blood.2020008248

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32877502

Fields of Study

Complement system in diseasesSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesBetacoronavirusCell LineComplement ActivationComplement C3Complement C5Complement Factor DComplement Factor HComplement Inactivating AgentsComplement Membrane Attack ComplexComplement Pathway, AlternativeHumansSARS-CoV-2Spike Glycoprotein, Coronavirus

MeSH Terms

BetacoronavirusSARS-CoV-2Cell LineComplement ActivationComplement Pathway, AlternativeComplement C3Complement C5HumansComplement Factor DComplement Membrane Attack ComplexComplement Factor HComplement Inactivating AgentsSpike Glycoprotein, Coronavirus

Keywords

Complement systemAtypical hemolytic uremic syndromeFactor HAlternative complement pathwayComplement factor BImmunologyComplement factor IComplement membrane attack complexAntibodyC3-convertaseThrombotic microangiopathyComplement component 5BiologyMedicineInternal medicine

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377.v1figshare

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380.v1figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386.v1figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389.v1figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392.v1figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392figshare

Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462395.v1figshare

Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462395figshare

Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462401.v1figshare

Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462401figshare